Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 11 art units • 12 examiners • 0 of 12 (0%) have an AI response strategy ready • 17 patents granted in the last 365 days
ImmunityBio Inc. has 12 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 12 distinct examiners and 11 distinct art units, indicating complete examiner dispersion with limited overlap among technical groups.
KONOPELSKI SNAVEL, SARA ELIZABETH is the busiest examiner, with 1 pending matter. Counsel should prioritize coordinated biotechnology claim review and individual prosecution records rather than an examiner-focused approach.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (17%) |
| §103 only | 3 (25%) |
| §112 only | 2 (17%) |
| Double-patenting + other | 2 (17%) |
| Multi-statute (no §101) | 3 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 35.0% | +35.4% |
| STAVROU, CONSTANTINA E | 1 | 42.4% | +35.6% |
| DUFFY, BRADLEY | 1 | 54.4% | +46.0% |
| ZAIDI, SYED A | 1 | 81.9% | +12.1% |
| WILLIAMS, KEITH RICHARD | 1 | 50.0% | +0.0% |
| WANG, RUIXUE | 1 | 55.9% | +19.0% |
| PETRASH, HILARY ANN | 1 | 65.6% | +50.2% |
| CARTER, SANDRA DILLAHUNT | 1 | 56.2% | +28.6% |
| ANDERSON-FEARS, KEENAN NEIL | 1 | 15.4% | +37.5% |
| MELCHIOR, JAMES RYLAND | 1 | 62.2% | +39.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19211886 | CONTENT AUTHENTICATION AND VALIDATION VIA MULTI-FACTOR DIGITAL TOKENS, SYSTEMS, AND METHODS | ZAIDI, SYED A | 23d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18225098 | COMPUTING AFFINITY FOR PROTEIN-PROTEIN INTERACTION | ANDERSON-FEARS, KEENAN NEIL | 22d overdue |
| 17767615 | Detecting Homologous Recombination Deficiencies (HRD) in Clinical Samples | LIN, JERRY | 16d |
| 18258925 | Fc-Receptor CAR Constructs and Cells | MELCHIOR, JAMES RYLAND | 54d |
| 18882219 | Nant COVID Vaccine Cross Reactivity | WANG, RUIXUE | — |
| 18509777 | Compositions And Methods Of MAIT Cell Activation | PETRASH, HILARY ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18225098 | COMPUTING AFFINITY FOR PROTEIN-PROTEIN INTERACTION | ANDERSON-FEARS, KEENAN NEIL | 22d overdue |
| 19277274 | COMPOSITIONS AND METHODS RELATED TO POTENT CYTOTOXIC M-CENK CELLS FROM CD3/CD14-DEPLETED APHERESIS PRODUCTS | DUFFY, BRADLEY | 12d |
| 19211886 | CONTENT AUTHENTICATION AND VALIDATION VIA MULTI-FACTOR DIGITAL TOKENS, SYSTEMS, AND METHODS | ZAIDI, SYED A | 23d |
| 18258925 | Fc-Receptor CAR Constructs and Cells | MELCHIOR, JAMES RYLAND | 54d |
| 19407885 | Interleukin-15, PD-1 Antibodies, and Taxanes in Non-Small Cell Lung Cancer | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 19357552 | DUAL-SPECIFIC BINDING MOLECULE USEFUL FOR ISOLATING SPECIFIC BLOOD CELLS | STAVROU, CONSTANTINA E | — |
| 18882219 | Nant COVID Vaccine Cross Reactivity | WANG, RUIXUE | — |
| 18509777 | Compositions And Methods Of MAIT Cell Activation | PETRASH, HILARY ANN | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1658 | 1 |
| 1632 | 1 |
| 1643 | 1 |
| 2432 | 1 |
| 1663 | 1 |
| 1672 | 1 |
| 1674 | 1 |
| 1687 | 1 |
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19407885 | Interleukin-15, PD-1 Antibodies, and Taxanes in Non-Small Cell Lung Cancer | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103DP | Final Rejection | — | Pending | Dec 03, 2025 |
| 19357552 | DUAL-SPECIFIC BINDING MOLECULE USEFUL FOR ISOLATING SPECIFIC BLOOD CELLS | STAVROU, CONSTANTINA E | 1632 | §103 | Final Rejection | — | Pending | Oct 14, 2025 |
| 19277274 | COMPOSITIONS AND METHODS RELATED TO POTENT CYTOTOXIC M-CENK CELLS FROM CD3/CD14-DEPLETED APHERESIS PRODUCTS | DUFFY, BRADLEY | 1643 | §103 | Final Rejection | 12d | Pending | Jul 22, 2025 |
| 19211886 | CONTENT AUTHENTICATION AND VALIDATION VIA MULTI-FACTOR DIGITAL TOKENS, SYSTEMS, AND METHODS | ZAIDI, SYED A | 2432 | §103 | Non-Final OA | 23d | Pending | May 19, 2025 |
| 18897262 | Methods And Systems For Producing A Protein Of Interest In A Plant | WILLIAMS, KEITH RICHARD | 1663 | §112 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18882219 | Nant COVID Vaccine Cross Reactivity | WANG, RUIXUE | 1672 | §102§103§112Other | Non-Final OA | — | Pending | Sep 11, 2024 |
| 18509777 | Compositions And Methods Of MAIT Cell Activation | PETRASH, HILARY ANN | 1644 | §102§103§112 | Non-Final OA | — | Pending | Nov 15, 2023 |
| 18497169 | MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF | CARTER, SANDRA DILLAHUNT | 1674 | §112 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18225098 | COMPUTING AFFINITY FOR PROTEIN-PROTEIN INTERACTION | ANDERSON-FEARS, KEENAN NEIL | 1687 | §101§103 | Non-Final OA | 22d overdue | Pending | Jul 21, 2023 |
| 18258925 | Fc-Receptor CAR Constructs and Cells | MELCHIOR, JAMES RYLAND | 1644 | §103§112 | Final Rejection | 54d | Pending | Jun 22, 2023 |
| 17767615 | Detecting Homologous Recombination Deficiencies (HRD) in Clinical Samples | LIN, JERRY | 1685 | §101§103 | Final Rejection | 16d | Pending | Apr 08, 2022 |
| 17630075 | ANTIBODY PRE-LOADED CD16+NK-92 CELLS AS AN EFFECTIVE THERAPEUTIC PRODUCT FOR TUMOR LYSIS | LU, CHENG | 1642 | §103§112DP | Non-Final OA | — | Pending | Jan 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmunityBio Inc. has 12 pending office actions as of October 2026, spread across 11 art units and 12 examiners.
Sara Elizabeth Konopelski Snavel has the most, with 1 of ImmunityBio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
